EpicentRx and Texas Children’s Cancer Center Announce the Initiation of a Phase 1 Clinical Trial with RRx-001 for Pediatric CNS Tumors

by EpicentRx | Feb 23, 2022 | 2022, Press Releases

TORREY PINES, Calif., Feb. 23, 2022 – EpicentRx, Inc., a clinical stage drug and device company, in collaboration with the Texas Children’s Cancer Center in Houston, today announced the start of a Phase 1 study to examine the safety and benefit of its lead small...

Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy

by EpicentRx | Jan 5, 2022 | 2022, Press Releases

Collaboration builds on recent data presented by Actinium at SITC demonstrating enhanced activity of targeted radiotherapies in combination with the anti-CD47 targeting antibody magrolimab in blood cancer and solid tumor models Collaboration to explore Actinium’s...

Several Players Begin 2022 with New Partnerships in Place

by EpicentRx | Jan 5, 2022 | Media

BioSpace

Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy

by EpicentRx | Jan 5, 2022 | Media

BioSpace

EpicentRx Publishes Proof-of-Concept Research on AdAPT-001

by EpicentRx | Dec 8, 2021 | 2021, Press Releases

Oncolytic Adenovirus in Phase 1 has extended half-life TGF-ß trap La Jolla, Calif., Dec. 8, 2021 – EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other...